What is Enhanc3D Genomics?
Enhanc3D Genomics is a specialized biotechnology firm operating as a spinout from the Babraham Institute in Cambridge, UK. Founded by leading academic scientists, the company focuses on the complex fields of regulatory genomics and chromosomal architecture. By mapping the 3D organization of the genome, Enhanc3D Genomics aims to unlock new insights into gene regulation, providing a foundational platform for therapeutic discovery and precision medicine. The company is currently supported by the StartCodon Accelerator, benefiting from the robust ecosystem of the Cambridge BioMedical Campus to translate high-level academic research into scalable, industry-ready solutions.
How much funding has Enhanc3D Genomics raised?
Enhanc3D Genomics has raised a total of $30.3M across 2 funding rounds:
Series A
$11.3M
Series A
$19M
Series A (2022): $11.3M with participation from Parkwalk Advisors, Bioqube Ventures, and BGF
Series A (2025): $19M led by BGF, Meltwind Advisory, and Parkwalk Advisors
Key Investors in Enhanc3D Genomics
BGF
BGF is a prominent UK-based investment firm that provides growth capital to small and mid-sized businesses across various sectors, supporting companies from early stages through to public listing.
Meltwind Advisory
Meltwind Advisory is a specialized firm founded by Jonathan Milner, focusing on due diligence and strategic investment in life science tools and platform therapeutics.
Parkwalk Advisors
Parkwalk Advisors is a leading investor in university spinouts, specializing in deeptech innovations and bridging the gap between academic research and commercial success.
What's next for Enhanc3D Genomics?
With the successful closure of this major enterprise-level funding, Enhanc3D Genomics is poised to transition from its foundational research phase toward more aggressive commercialization and clinical validation. The strategic allocation of these funds will likely prioritize the expansion of their proprietary technology platform, enabling deeper exploration of the non-coding genome and its implications for disease pathology. Furthermore, the company is expected to strengthen its internal talent pool and forge additional industry partnerships to expedite the development of its therapeutic pipeline. As the firm continues to mature, the focus will remain on bridging the gap between academic innovation and tangible patient outcomes, ensuring that their advancements in chromosomal architecture translate into meaningful breakthroughs in the life sciences market.
See full Enhanc3D Genomics company page
